LSI’s Post

“We need to think about servicing these potential customer sets who will be using and view robotics in a very different way from the current customer base.” Surgical robotics are more prevalent today than ever before. By 2028, it’s projected that nearly 1 million surgeries in the US will be performed each year using robotics. As the landscape evolves, pinpointing which robotic systems will best meet patient needs and streamline surgeries, in what specific settings of care, is essential. At #LSIUSA24, our panelists explored the nuances of integrating surgical robotics across different healthcare settings, discussed the strategies for overcoming barriers to access, and the future implications of robotic surgery on healthcare delivery and patient care. The full panel, ‘The Stratification of Surgical Robotics: The Right Equipment in the Right Place for the Right Patient’ is now available on our website and YouTube channel. Tune in to hear from this incredible group of panelists:  • Joe Mullings (Moderator) — The Mullings Group • Greg Roche — Distalmotion • Evelyn T. — LSC - LifeSciences Consultants • Mike Clouthier — Medtronic • Scott Huennekens — Front Foot Ventures Want to see more content like this? Join us at LSI Europe ‘24 this September 16th - 20th in Portugal. Secure your spot today, to ensure you get the best rate and secure a hotel room onsite at the Penha Longa Resort.

🌍 Global Surgical Robots Market 2030: Transforming Healthcare with Precision and Innovation 🏥 The surgical robots market is poised for remarkable growth, with advancements in robotic technology revolutionizing the healthcare industry. By 2030, the market is expected to reach unprecedented heights, driven by the increasing adoption of minimally invasive surgeries, enhanced precision in surgical procedures, and a growing focus on patient outcomes. Explore our in-depth analysis on the future of surgical robots, highlighting key trends, market drivers, and the impact of cutting-edge innovations in robotic-assisted surgeries. From improved patient safety to reduced recovery times, surgical robots are reshaping the landscape of modern medicine. 🔗 Discover more insights in our comprehensive report: https://lnkd.in/gFmD97Yn #HealthcareInnovation #SurgicalRobots #MinimallyInvasiveSurgery #MedicalTechnology #RoboticSurgery #HealthcareTrends#MedTech #HealthcareFuture #SurgicalInnovation #RoboticsInHealthcare #AdvancedSurgery #PatientCare #RoboticAssistedSurgery #HealthcareTechnology #SurgeryTrends #TechInMedicine #FutureOfSurgery #GlobalHealthcare #MedicalDevices #SurgicalAdvancements #HealthcareMarket #RoboticTechnology #WissenResearch

In the North America surgical robotics domain, key players like 𝐈𝐧𝐭𝐮𝐢𝐭𝐢𝐯𝐞 𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥, 𝐒𝐭𝐫𝐲𝐤𝐞𝐫 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧, and 𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜 are fostering innovation with advanced robotic systems. 𝑇ℎ𝑒𝑠𝑒 𝑡𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑖𝑒𝑠, 𝑖𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑖𝑛𝑔 𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑑 𝑖𝑚𝑎𝑔𝑖𝑛𝑔, 𝑛𝑎𝑣𝑖𝑔𝑎𝑡𝑖𝑜𝑛 𝑎𝑠𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒, 𝑎𝑛𝑑 𝑒𝑟𝑔𝑜𝑛𝑜𝑚𝑖𝑐 𝑑𝑒𝑠𝑖𝑔𝑛𝑠, 𝑎𝑟𝑒 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑠𝑢𝑟𝑔𝑖𝑐𝑎𝑙 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑎𝑛𝑑 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑎𝑐𝑟𝑜𝑠𝑠 𝑡ℎ𝑒 𝑟𝑒𝑔𝑖𝑜𝑛. One eminent example is 𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜'𝐬 𝐇𝐮𝐠𝐨𝐓𝐌 𝐫𝐨𝐛𝐨𝐭𝐢𝐜-𝐚𝐬𝐬𝐢𝐬𝐭𝐞𝐝 𝐬𝐮𝐫𝐠𝐞𝐫𝐲 (𝐑𝐀𝐒) 𝐬𝐲𝐬𝐭𝐞𝐦, which was launched 𝐢𝐧 𝟐𝟎𝟐𝟑. This innovative technology has been integrated into healthcare facilities like 𝐓𝐨𝐫𝐨𝐧𝐭𝐨 𝐆𝐞𝐧𝐞𝐫𝐚𝐥 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥, reflecting the rapid adoption of robotic technologies. Leading this technological revolution are institutions like the 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 𝐇𝐞𝐚𝐥𝐭𝐡 𝐍𝐞𝐭𝐰𝐨𝐫𝐤 (𝐔𝐇𝐍). They utilize platforms such as the 𝐃𝐚 𝐕𝐢𝐧𝐜𝐢 𝐗𝐢 and 𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜 𝐇𝐮𝐠𝐨 𝐫𝐨𝐛𝐨𝐭𝐬 to redefine surgical care standards. In 2023, 𝐌𝐨𝐨𝐧 𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥'𝐬 𝐌𝐚𝐞𝐬𝐭𝐫𝐨 𝐬𝐲𝐬𝐭𝐞𝐦 was utilized in the first US clinical procedures, aiding in weight loss surgeries. The FDA-cleared system enhanced laparoscopy procedures, as demonstrated by three surgeons at 𝐁𝐚𝐩𝐭𝐢𝐬𝐭 𝐇𝐞𝐚𝐥𝐭𝐡 in Florida. These efforts, in turn, represent a holistic approach toward enhancing precision and improving patient outcomes in medical procedures. For a deeper grasp of advancing efforts to reduce invasiveness and optimization of medical procedures, please refer to the detailed summary of the 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐑𝐨𝐛𝐨𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 here: https://lnkd.in/d9GC4rm4 . . . Ethicon, Inc. Zimmer Biomet Smith+Nephew Accuray #surgicalrobotics #surgicalrobots #healthcare #surgicaldevices #robotics #roboticsystem #marketresearch #inkwoodresearch

Discover how medical robotics is transforming healthcare, from enhancing surgical precision to improving rehabilitation and expanding remote care access. Learn about the benefits, applications, and future prospects of this revolutionary technology. #MedicalRobotics #PharmacyAutomation #RehabilitationRobotics #roboticpharmacy #SurgicalRobots #TelepresenceRobots

Robotic Assisted Surgery will be part of the future portfolio of all leading medtech companies. Prerequisites are: 1. Innovation: Develop cutting-edge technology that offers unique features or improvements over existing systems. This could include advancements in surgical capabilities, ergonomics, visualization, or integration with other healthcare systems. 2. Cost-effectiveness: Offer competitive pricing and cost-effective solutions to make robotic-assisted surgery more accessible to a wider range of healthcare providers. 3. Training and Support: Provide comprehensive training programs and ongoing support to healthcare professionals to ensure successful adoption and utilization of robotic systems. 4. Clinical Evidence: Generate strong clinical evidence demonstrating the efficacy, safety, and cost-effectiveness of your robotic-assisted surgery systems compared to competitors. 5. Partnerships and Collaborations: Form strategic partnerships with hospitals, healthcare systems, and research institutions to promote adoption and drive innovation in the field. 6. Regulatory Compliance: Ensure compliance with regulatory requirements and standards to instill confidence in the safety and effectiveness of your products. 7. Customer Satisfaction: Focus on customer satisfaction by delivering reliable, user-friendly systems and responsive customer support services.

AI in Action: EndoQuest Robotics Secures $42M to Transform Luminal Surgeries EndoQuest Robotics™ Robotics secures $42M in C-1 funding to propel the development of flexible endoluminal robotic technologies for minimally invasive surgeries. Led by CE Ventures (CEIIF) and McNair Interests, with Puma Aztec Ventures B.V. Capital LLC as a new investor, the funding aims to advance R&D, achieve regulatory milestones, and commercialize their innovative robotic system. Headed by CEO Kurt Azarbarzin, EndoQuest focuses on leveraging AI in their flexible robotic platform to revolutionize gastrointestinal and luminal surgeries. The emphasis on precision and minimally invasive interventions underscores their commitment to enhancing patient outcomes and signifies a significant stride in the field of AI-driven medical robotics. #EndoQuestRobotics #C1Funding #MedicalRobotics #AIInAction #FlexibleRoboticTechnologies #MinimallyInvasiveSurgery #CEventures #McNairInterests #PumaVentureCapital #AIInnovation #R&D #RegulatoryMilestones #RoboticSystem #KurtAzarbarzin #AIinMedicine #PrecisionMedicine #PatientOutcomes #TechFunding #MedicalTech #TechInnovation #EndoQuestFunding

Medical Robotics Market Size, Share & Trends Analysis Report By Product (Noninvasive Radiosurgery Robots, Hospital & Pharmacy Robotic Systems, Surgical Robotic Systems, Rehabilitative Robotic Systems, Other Robotic Systems), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐯𝐭. 𝐋𝐭𝐝. 𝐆𝐞𝐭 𝐭𝐡𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dgaN7QaA The medical robotics market is witnessing significant growth due to the rising demand for minimally invasive surgeries and precision treatments. Robotics in healthcare is enhancing patient outcomes by reducing recovery times, improving surgical accuracy, and enabling remote surgery. The integration of AI and advanced imaging systems is driving innovations in robotic surgery, rehabilitation, and hospital automation. #medicalrobotics 𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 ARxIUM Asensus Surgical Auris Health, Inc. Auris Surgical Robotics, Inc. Avra Medical Robotics, Inc. BD CORINDUS VASCULAR ROBOTICS IN DENSO Ekso Bionics Elekta FREEHAND 2010 LIMITED Globus Medical Hansen Medical Health Robotics Hocoma Houston Medical Robotics, Inc. HD Hyundai Heavy Industries., Immersion Corporation Intuitive Johnson & Johnson Kirby Lester, Pharmacy Automation by Capsa Healthcare MAKO Surgical Corp. MAZOR ROBOTICS LLC McKesson Medrobotics Corporation. Medtronic

We may be witnessing the early days of the bundling of surgical and interventional platforms of robots. It may also add credence to heading to the ASC’s right now if you are going to be releasing a surgical or interventional robotic platform any time soon. Reminder to not fight a kickboxer in a ring. Drag the fight to a phone booth. The strategy that Intuitive is using that is one of the critical components to the rapid deployment of the Ion system as well as its new Davinci 5 Tower is in plain sight if you are willing to look. It is happening on a few fronts. Intuitive’s sales and clinical teams from soft tissue have paved the way for the Ion system. The bundling potential of digital surgical and interventional robotic platforms with this playbook should be horrifying to the large strategics. Stryker is feeling it on their 1788 towers reorder / upgrade plans. Whereas until the release of the DaVinci 5, there would be a brand affinity as well as technical advantage to the current stack holder incumbent in the OR. Not so fast. Even the best Stryker reps are starting to hear from hospitals, “Instead of ordering five of the 1788’s, we are going to order three, because we can utilize the tower on the incoming DaVinci 5 System”. There is concern. While Johnson & Johnson with their #Monarch System and Noah Medical with #Galaxy are trying to grab market share while Intuitive is using its existing customer base built over time through the Si, Xi, and now Davinci 5 to plow through and grab the early users. That conversation with the squad of Intuitive soft tissue and Ion sales and clinical teams together goes something like: Want to trade out or upgrade your current Intuitive soft-tissue system? Sure thing. Why don’t we trade out the three Xi’s for a few Davinci 5’s and we will throw in two Ion Systems into the deal, no charge. 1-year lease – no problem Fee per use – no problem We will come back around and renew the lease with our next amazing platform. Yes, that’s the sound of a door being slammed shut on competition. When you can dominate on the economic front, technical front, and have a stronghold in soft tissue and then start to use that playbook and a powerful lever arm into other markets, the outcomes are not too difficult to extrapolate. The emerging endoluminal and endovascular markets are even bigger than the current soft tissue robotics market. Intuitive is going there. Currently it will likely be hospital based as the economics and influence are more easily scalable there. As a competitor, how far is too far gone? When do you decide to get into the fight or not into the fight with a massively successful digital surgery / interventional robot so that you can claim excellence to battle against the incumbent? Is there a way to leverage bundling strategies from the other end on your current position with other products you sell into the hospital? How much time do you have?

How I missed Intuitive Surgical's ascent three times! In our latest thought piece we discuss how dislodging them from leadership in medical robotics will be extremely difficult. #ISRG #IntuitiveSurgical #medicalrobotics https://lnkd.in/ewJrGrv4